Needham Lifts Taysha Gene Therapies (TSHA) PT to $8, Cites Positive Clinical Data

On June 2, Needham raised its price target for Taysha Gene Therapies Inc. (NASDAQ:TSHA) to $8 from $6, while maintaining a Buy rating on the stock. This adjustment follows the company’s recent release of updated clinical data from its adult and pediatric REVEAL studies for TSHA-102 and details regarding an FDA-aligned pivotal study design. Needham particularly highlighted the evidence of dose-dependence as further de-risking for TSHA-102.

A laboratory technician preparing a gene therapy sample in a sterile environment.

In Q1 2025, Taysha reported regulatory and clinical progress with its TSHA-102 program for Rett syndrome. The TSHA-102 gene therapy has shown promising results in clinical trials, with patients showing functional gains in fine motor and gross motor, which is not typically observed in untreated populations. Taysha has completed dosing in the dose escalation portion of its REVEAL Phase 1/2 trials and reported no treatment-related serious adverse events or dose-limiting toxicities.

Taysha reported $116.6 million in cash and cash equivalents as of March 31, which is expected to support operations into Q4 2026. The company plans to provide an update on its pivotal Part B trial design and clinical data at the upcoming International Rett Syndrome Foundation’s 2025 Scientific Meeting. However, the timeline for initiating the pivotal trial and achieving regulatory approval remains uncertain.

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company. It develops and commercializes adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.

While we acknowledge the potential of TSHA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSHA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.